Company intelligence / Profile preview
Entera Bio Ltd.
Jerusalem, Jerusalem, Israelenterabio.com ↗
- Ownership
- Public · ENTX
- Employees
- ~19
- Development stage
- Phase 2
01
Overview
Entera Bio’s lead candidate EB613, an oral formulation of PTH(1–34), has completed a successful Phase II trial for osteoporosis with positive bone mineral density results and is advancing to Phase III. EB612 for hypoparathyroidism has completed a successful Phase II trial meeting its primary endpoint. Additional programs include oral oxyntomodulin for obesity/metabolic disease and oral GLP2 for short bowel syndrome[5][8].
- Therapeutic areas
- GastroenterologyEndocrinologyMetabolic Disorders
- Modalities
- PeptidesProteins (biologics)Oral macromolecule therapeutics
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
OPKO Health / OPKO Biologics Inc. – collaboration on oral GLP1/glucagon candidate for obesity/metabolic disease[2].Amgen – strategic research collaboration on application of platform technology to proprietary compounds[6].
04
Financials
- Market cap
- $148.4M
- Total revenue
- $0
- Enterprise value
- $137.5M
Beyond the preview
Go deeper on Entera Bio Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Entera Bio Ltd..